Pharmacological strategies for treating misfolded rhodopsin-associated autosomal dominant retinitis pigmentosa

Yibo Xi, Yuanyuan Chen

Mutations that cause protein misfolding are implicated in conditions such as retinitis pigmentosa (RP), Usher Syndrome, and myocilin-associated primary open angle glaucoma. The aggregation and continuous degradation of a highly abundant misfolded protein add proteolytic load of the affected cells. The subtle balance of cellular homeostasis, once disrupted by an overwhelmed proteolytic system, will lead to cell death and tissue degeneration. This perspective uses RHODOPSIN (RHO)-associated RP to review pharmacologic strategies for modifying protein misfolding-associated abnormalities with the goal of bringing insights to the treatment of other proteinopathies.

RHO mutations and RP: RP is the most common inherited retinal degeneration, affecting 1/4000 and, in total, over 1,000,000 people worldwide (Hartong et al., 2006). Genetic mutations lead to abnormalities of rods or retinal pigment epithelium that manifest as nyctagopia and progressive visual field defects beginning peripherally. As the disease advances, central vision is initially maintained; however, eventual secondary loss of cone cells in the fovea can cause legal blindness in some end-stage RP patients. Onset typically occurs in young adulthood and the progression of the disease varies from years to decades. Acquired vision loss severely affects quality of life, and visual disability can additionally have profound psychosocial morbidity. These characteristics highlight the urgent need for safe and efficacious treatment of this currently untreatable disease.

Mutations in the RHODOPSIN (RHO) gene account for 25–30% of all autosomal dominant RP (adRP) cases. The first identified RP mutation is the RHO P23H mutation, which happens to be the most common adRP mutation in the USA. Among the 150+ RHO mutations that cause RP, only four mutations are associated with autosomal recessive RP—the remainder cause adRP mainly via dominant negative effects (https://sph.uth.edu/retnet/). The class II RHO mutations contain over 50 single mutations that destabilize the native structure of rhodopsin and lead to its misfolding. These mutations are mostly localized on the extracellular loop and plug motifs, as well as within the transmembrane domains.

As a photopigment, rhodopsin is the most abundant protein located in the outer segments (OS) of rods, and it enables the characteristic high photosensitivity (Palczewski, 2006). Binding with an 11-cis-retinal chromophore allows photoactivation of rhodopsin and initiation of visual phototransduction. Biosynthesis of rhodopsin reaches about 6 million molecules per day per rod, lasting for the cell’s entire life span. The biosynthesis of rhodopsin requires highly coordinated regulation of the RHO gene expression, protein translation and folding, glycosylation, palmitoylation, and transport to the OS. Dysregulation of any of these steps can lead to rod stress and death. As a class A G-protein coupled receptor and a membrane protein that is not as stable as soluble proteins, the folding of a nascent aporprotein rod opsin is supported and monitored by molecular chaperones in the endoplasmic reticulum (ER) (Athanasiou et al., 2018). Misfolded rhodopsin activates the ER associated protein degradation (ERAD) pathway, leading to its degradation by the ubiquitin-proteasome system or the lysosome system (Figure 1A). Mutations that cause rhodopsin misfolding continuously activate the ERAD pathway, and the overwhelmed proteolytic system eventually results in rod death. In the OS disc membranes, the photobleached rhodopsin finally releases all-trans-retinal and converts to rod opsin for pigment regeneration. The rod opsin mutants, lacking any ligand to stabilize its structure during pigment regeneration, is highly vulnerable to misfolding; this misfolded rod opsin can disrupt the OS membrane structure and add to rod stress.

Pharmacological strategies to rescue rods by restoring rhodopsin homeostasis: The pharmacological strategies discussed here are targeting on restoring rhodopsin homeostasis in preventing rod death for early and mid-stage adRP. Strategies aimed at preserving central vision and restoring vision in advanced RP are discussed in other reviews such as (Dalkara et al., 2016).

Chaperones stabilize the native folding of mutant rhodopsins: One strategy is to support the folding of the mutant rhodopsin by boosting the molecular chaperone activity, or by delivering small molecule chaperones (Figure 1B). While supplementation with vitamin A has shown efficacy in delaying disease progression in some RP patients, the lack of genetic diagnosis in these early studies makes the correlation of vitamin A with specific RP variants difficult. Genetic overexpression of molecular chaperones such as the 78-kDa glucose-regulated protein (GRP78/Bip) showed retinal protection in the transgenic rats expressing RHOcis (Gorbatyuk et al., 2010), thus supporting the hypothesis that photoreceptors can be rescued by providing sufficient support during folding. Based on this notion, chemical chaperones (4-phenylbutyric acid) and retinoid analogues (11-cis-locked retinals, retinobenzaldehydes, beta-ionone, and NSC45012) have been tested in vitro with the demonstration of folding improvement of the mutant rod opsin and increased transport to the plasma membrane in mammalian cells (Athanasiou et al., 2018). However, most of these small molecule chaperones have no published records of in vivo efficacy notwithstanding a recent report of daily oral 4-phenylbutyric acid being retinal-protective in the Rho231H−/− knock-in mouse model (Qi et al., 2019).

To overcome this barrier, we used an unbiased cell-based high-throughput screening method to screen over 69,000 small molecules and identified a group of small molecules, including YC-001, as non-retinoid chaperones of rod opsin protein. We found YC-001 rescued the cellular transport of multiple misfolded rhodopsin mutants from ER to the plasma membrane with micromolar potency and low cytotoxicity. Unlike 9-cis-retinal, YC-001’s chaperone activity is light-independent. The advantage of developing a non-retinoid chaperone is that it binds to rod opsin via non-covalent interactions to provide extra structural support for opsin while the native 11-cis-retinal is not sufficient. Additionally, it does not prohibit the visual pigment formation that is essential for phototransduction and visual function. We showed that a single intraperitoneal injection of YC-001 successfully protects the Abaco4−/−, Rdh8−/− double knockout mice from bright light damage, suggesting an in vivo retinal protective effect of YC-001 (Chen et al., 2018). Due to the short serum half-life of YC-001, we are actively working to optimize the chemical properties of YC-001 analogues to improve its stability in vivo for testing its chronic retinal protection in the Rho231H−/− knock-in mouse model of adRP.

Pharmacological clearance of misfolded rhodopsin: Alternatively to rescuing folding, we also seek to rescue rods by inducing the degradation of the misfolded rhodopsin protein (Figure 1B). Previous studies showed that selectively digesting the mRNA of the mutant RHO by gene delivery of a hammerhead ribozyme exhibited long-term retinal protection in the Rho231H−/− transgenic
Using a luciferase reporter assay (Figure 2A), we performed a small-molecule high-throughput screening of 68,979 compounds (Figure 2B) and identified 9 compounds that selectively reduced the misfolded P23H rod opsin without an effect on the wild type rod opsin protein. Further, we found that five of these compounds, including methotrexate (MTX), promoted the degradation of misfolded rod opsin mutants. MTX, a drug commonly used off-label for treating retinal edema, already has rich documentation of its ocular pharmacokinetics and safety. MTX also showed higher selectivity in clearing mutant than WT rhodopsin (Figure 2C). Given this evidence, we selected MTX for a pilot study investigating its mechanism of action and efficacy. By pharmacologically blocking the proteasomal and the lysosomal pathways, we showed MTX induced degradation of P23H rod opsin via the lysosomal, but not the proteasomal pathway in the NIH3T3 cells. An intravitreal injection of MTX also increased the autophagy flux in vivo in the Rho\textsuperscript{P23H/+} mouse retina, suggesting MTX clears misfolded rhodopsin mainly via the autophagy-lysosome pathway. Importantly, one intravitreal injection of 25 pmol MTX at postnatal day (PND15) increased electroretinogram (ERG) response and rhodopsin level in the retinæ of Rho\textsuperscript{P23H/+} knock-in mice at one month of age. Further, four weekly intravitreal injections increased the photoreceptor cell number in the retinæ of Rho\textsuperscript{P23H/+} mice compared to vehicle control. Our study showed a therapeutic potential of repurposing MTX for the treatment of RHO-associated RP.

MTX boosted the selective clearance of Rho\textsuperscript{P23H/+} in vitro but increased total rhodopsin level in vivo in the Rho\textsuperscript{P23H/+} mouse retina. We showed that the autophagy flux was increased 48 hours after an intravitreal injection of MTX in the Rho\textsuperscript{P23H/+} mice, thus these counter-intuitive observations are actually not conflicting. The increased rhodopsin immunofluorescence by MTX treatment was mainly on the OS layer, but not the outer nuclear layer, suggesting the rhodopsin was properly folded and transported and thus it was mainly the
WT rhodopsin. Co-expressed with the misfolded rhodopsin mutant, WT rhodopsin co-aggregates in the ER in mammalian cell culture and can get degraded by the ERAD pathway. Thus, by selectively inducing the degradation of the misfolded rhodopsin mutant, more WT rhodopsin was transported to the OS layer by MTX *in vivo*. The direct molecular target of MTX that boosted rhodopsin degradation is still unknown and requires further investigation.

In addition to MTX, we also identified four other compounds that selectively increased misfolded rod opsin’s degradation in *vivo*. These compounds include: CL-001 (Pubchem ID 11715767, EC50 = 2.1 µM by the RhoP23H immunostaining and high-content imaging assay), CL-002 (Pubchem ID 622442, EC50 = 1.6 µM), CL-005 (Pubchem ID 10091681, EC50 = 1.3 µM) and CL-007 (Pubchem ID 5330790, EC50 = 2.9 µM). Whereas CL-002 has no record on pharmacological activities, CL-001 and CL-007 are both pan-inhibitors of cyclin-dependent kinases (CDKs), and CL-005 is an inhibitor of the prolyl hydroxylase, thus a stabilizer of heat shock-induced factor 1α (HIF1α). Even though chemoinformatics of these hits indicate that CDKs may regulate rhodopsin degradation, reports about the retinal toxicity of CDK inhibitors (Illesan et al., 2006) suggest further identification of the specific CDK or other kinase that regulates rhodopsin degradation and development of selective CDK inhibitors in the future.

Preconditioned hypoxia has shown protection against retinal degeneration in rodents (Grimm et al., 2005) and prolyl hydroxylase inhibitors have shown cellular protection from harmful conditions *in vitro* by inducing autophagy (Singh et al., 2020). Future investigations will test the hypothesis of autophagy-mediated rhodopsin degradation by stabilizing HIF1α and evaluate its potential for treating RP.

**Immune response and retinal degeneration:**

Immune responses are associated with retinal degeneration. Microglia serve as innate immune surveillance and they play a neurotrophic role in phagocytosing retinal degeneration. Microglia produce a large amount of proinflammatory cytokines, recruiting myeloid cells, and their infiltration to the degenerative retina may contribute to photoreceptor loss (Rashid et al., 2019). MTX is a potent inhibitor of dihydrofolate reductase, this leads to its use in treating various cancers at high doses and rheumatoid arthritis at low dose (Maksimovic et al., 2020). At low dose, MTX shows strong anti-inflammatory effects by increasing adenosine release which suppresses activities of the immune cells including neutrophils, monocytes/macrophages, dendritic cells, and lymphocytes. Clinically, MTX is intravitreally injected to treat ocular inflammations such as retinal edema. We do not know yet whether the retinal protection by MTX in the RhoP23H mice *in vivo* is also due to the potent anti-inflammatory effects, and this question will be addressed soon.

**Conclusion and perspective:**

Rhodopsin misfolding due to genetic mutation disrupts the protein homeostasis in rods and leads to adRP. We have developed two pharmacological strategies to restore the homeostasis of this highly abundant membrane protein. The non-retninoid chaperones, such as YC-001, provide additional structural support to the rod opsin mutants via non-covalent interactions, which rescue the folding and transport of the rod opsin mutants to the target membrane without blocking pigment regeneration during the visual cycle. Alternatively, degradation inducers, such as MTX, selectively clear the misfolded rhodopsin protein, providing improved homeostasis for WT rhodopsin and a longer lifespan of rods. Future studies will be focused on improving the chemical properties of these two groups of compounds to increase retinal bioavailability and half-life, or the development of slow ocular release formula to achieve long-term efficacy and safety for treating RHO-associated adRP.

We thank Owen Clinger for his efforts on editing this perspective.

The present work was supported by the NIH Grants R01 EY030991 to YC and the P30 EO08098 to the Department of Ophthalmology at University of Pittsburgh, the Ear and Eye Foundation of Pittsburgh and an unrestricted grant from Research to Prevent Blindness, New York, NY, USA.

**Yibo Xi, Yuanyuan Chen**

Department of Ophthalmology, University of Pittsburgh, Pittsburgh, PA, USA (Xi Y)

Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA, USA (Chen Y)

McGowan Institute of Regenerative Medicine, University of Pittsburgh, Pittsburgh, PA, USA (Chen Y)

*Correspondence to: Yuanyuan Chen, PhD, chenyl@pitt.edu.*

https://orcid.org/0000-0001-9625-1610

(Yuanyuan Chen)

**Date of submission:** November 4, 2020

**Date of decision:** December 21, 2020

**Date of acceptance:** February 9, 2021

**Date of web publication:** June 7, 2021

https://doi.org/10.4103/1673-5374.314306

How to cite this article: Xi Y, Chen Y (2022) Pharmacological strategies for treating misfolded rhodopsin-associated autosomal dominant retinitis pigmentosa. *Neural Regen Res* 17(1):110-112.

**Copyright license agreement:** The Copyright License Agreement has been signed by both authors before publication.

**Plagiarism check:** Checked twice by iThenticate.

---

**Peer review:** Externally peer reviewed.

**Open access statement:** This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

**References**

Athanasiou D, Aguila M, Bellingham J, Li W, McCulley C, Reeves PJ, Cheetham ME (2018) The molecular and cellular basis of rhodopsin retinitis pigmentosa reveals potential strategies for therapy. *Prog Retin Eye Res* 62:1-23.

Chen Y, Chen Y, Jastrzebska B, Golczak M, Gulati S, Tang H, Seibel W, Li X, Ji H, Han Y, Gao S, Zhang J, Liu X, Heidari-Torkabadi H, Stewart PI, Harte WE, Tochtrop GP, Palczewski K (2018) A novel small molecule chaperone of rod opsin and its potential therapy for retinal degeneration. *Nat Commun* 9:1976.

Dalkara O, Goureau O, Marazova K, Sahel JA (2016) Let there be light: gene and cell therapy for blindness. *Hum Gene Ther* 27:134-147.

Gorbatyuk MS, Knox T, LaVail MM, Gorbatyuk OS, Niewoehner SM, Hauswirth WW, Lin HJ, Muzyczka N, Lewin AS (2010) Restoration of visual function in P23H rhodopsin transgenic rats by gene delivery of Bif/Gpr78. *Proc Natl Acad Sci U S A* 107:5961-5966.

Grimm C, Herrmann DM, Bogdanova A, Hotop S, Kilic U, Wenzel A, Kilic E, Gassmann M (2005) Neuroprotection by hypoxic preconditioning: HIF-1 and erythropoietin protect from retinal degeneration. *Semin Cell Dev Biol* 16:531-538.

Hartog DT, Benson EL, Dryja TP (2006) Retinitis pigmentosa. *Lancet* 368:1795-1809.

Illesan O, Anderson S, Niesman M, Zwick L, Jessen BA (2006) Retinal and peripheral nerve toxicity induced by the administration of a pan-cyclin dependent kinase (cdk) inhibitor in mice. *Toxicol Pathol* 34:243-248.

Lewin AS, Drenser KA, Hauswirth WW, Nichikawa S, Yasumura D, Flannery JG, LaVail MM (1998) Ribozyme rescue of photoreceptor cells in a transgenic rat model of autosomal dominant retinitis pigmentosa. *Nat Med* 4:967-971.

Liu X, Feng B, Vats A, Tang H, Seibel W, Swaroop M, Tawa G, Zheng W, Byrne L, Schurk M, Chen Y (2020) Pharmacological clearance of misfolded rhodopsin for the treatment of RHO-associated retinitis pigmentosa. *FASEB J* 34:10146-10167.

Lobanova ES, Finkelstein S, Li, Travis AM, Hao Y, Klingeborn M, Skiba NP, Deshaies RJ, Arkashvly YV (2018) Increased proteasomal activity supports photoreceptor survival in inherited retinal degeneration. *Nat Commun* 9:1738.

Maksimovic V, Pavlovic-Popovic Z, Vukovic B, Cvejic J, Mooranian A, Salimi H, Mikov M, Golocorbin-Korban K (2020) *Molecular mechanism of action and pharmacokinetic properties of methotrexate*. Mol Biol Rep 47:4690-4708.

Palczewski K (2006) *G protein-coupled receptor 1*. *Science* 312:530-533.

Perspective

Tochtrop GP, Palczewski K (2018) A novel small molecule chaperone of rod opsin and its potential therapy for retinal degeneration. *Nat Commun* 9:1976.

Rashid K, Akhtar-Schaefer I, Langmann T (2019) *The molecular mechanism of action and pharmacokinetic properties of methotrexate*. *Mol Biol Rep* 47:4690-4708.

Qiu Y, Yao J, Jia L, Thompson DA, Zacks DN (2019) *Hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitors induce autophagy and have a protective effect in an in-vitro ischemia model*. *Sci Rep* 10:1597.

---

C-Editors: Zhao M, Liu WJ, Qiu Y, F-Editor: Jia Y